Inside This Issue: Sleep Apnea
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Highlights from 10th Annual Conference on Alzheimer's Drug Discovery
Featured Company: ImThera
Subscribe now to access over 45 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: San Francisco and Boston Lead Neurotech Development Clusters
NeuroInsights and the Neurotechnology Industry Organization released a new study at the Society for Neuroscience Annual Meeting in Chicago this month outlining the metropolitan regions around the world leading the way in commercial neuroscience. The San Francisco Bay Area (score: 100) and Greater Boston (98) top the list, followed by New York/New Jersey (91), Greater London (84), San Diego (83), Los Angeles/Irvine (81), Baltimore (69), Greater Philadelphia (66) and Minneapolis (53), according to the study "Neurotech Clusters 2010: Mapping the Business of Neuroscience."...
New Sleep Apnea Treatments on the Horizon
Sleep Apnea Syndromes are a group of disorders where the patient repeatedly stops breathing (apnea) during sleep. To qualify as sleep apnea, examination and tests need to show breathing stops that last for more than 10 seconds each and occur as often as 20 times or more per hour, causing a measurable drop in blood oxygenation levels.Companies mentioned include Apnex Medical, Cephalon, Collegium, Cortex Pharmaceuticals, Galleon, Imthera, Inspire, Medtronic, ResMed, Sanofi-Aventis, Sepracor, SomnoMed, Takeda, Vivus, and UCB.
ImThera Unveils Sleep Apnea Neurostimulation Device
ImThera was founded in 2004 by now CEO Marcelo Lima. The company is based in San Diego and has five full time employees and six part time workers. Its product is an implantable device that stimulates the hypoglossal nerve to increase the tone of several tongue muscles. In doing so, the device prevents a relaxation of the tongue that is common in obstructive sleep apnea (OSA) patients and leads to airway blockage. Lima came up with the idea after his brother-in-law, a sleep apnea patient, was unable to comply with the then-recommended treatment known as CPAP.
Companies Covered In This Issue Include: Acadia Pharma, Acorda Therapeutics, Amarantus, Affiris, Alkermes, Amarin, Amicus, Anesiva, Apnex Medical, BioMarin, Biovail, Blackrock, Cephalon, Collegium, Cortex Pharmaceuticals, CVRx, Curemark, Depomed, Endogastric Solutions, Epix, Enteromedics, Envoy, Forest, Flexion, Galleon, Geodon, GSK, Hepartes, Huxley, Hydra Biosciences, Icagen, Impax, Imthera, Inspire, iPerian, Martek Biosciences, Medtronic, Merz Pharma, Metabolic Solutions Inc, Omeros, Opthotech, MJ Fox Foundation, Nabi, NeuroVigil, NeuroVista, Novartis, Otokinetics, Oxford BioMedica, Penumbra, Phytopharm, Prosensa, ResMed, Rexahn, RhinoCyte, Roche, Satiety, Sanofi-Aventis, Sepracor, Shire, Sirion Holdings, Somanetics, SomnoMed, Targacept, Takeda, Teva, Titan, Transcept, Vivus, UCB, Xenoport and Zogenix
Subscribe Now:
|
|
